Table 1.
Patient Characteristics
| Total (n=138) | TARE (n=54) | TACE (n=84) | P value | SMD | |
|---|---|---|---|---|---|
| Age, median (range) | 59 (33–87) | 58 (33–83) | 60 (40–87) | 0.82 | −0.026 |
| Male, n (%) | 115 (83.3%) | 45 (83.3%) | 70 (83.3%) | 1.00 | 0.000 |
| Etiology, n (%) | 0.15 | −0.096 | |||
| HBV | 97 (70.3%) | 42 (77.8%) | 55 (65.5%) | ||
| HCV | 12 (8.7%) | 3 (5.6%) | 9 (10.7%) | ||
| Alcohol | 11 (8.0%) | 2 (3.7%) | 9 (10.7%) | ||
| HBV + HCV | 1 (0.7%) | 1 (1.8%) | 0 (0.0%) | ||
| HBV + Alcohol | 6 (4.4%) | 0 (0.0%) | 6 (7.1%) | ||
| HCV + Alcohol | 2 (1.4%) | 0 (0.0%) | 2 (2.4%) | ||
| HBV + HCV + Alcohol | 1 (0.7%) | 1 (1.8%) | 0 (0.0%) | ||
| Unknown | 8 (5.8%) | 5 (9.3%) | 3 (3.6%) | ||
| ECOG performance status, n (%) | 0.53 | −0.108 | |||
| 0 | 123 (89.1%) | 47 (87.0%) | 76 (90.5%) | ||
| 1 | 15 (10.9%) | 7 (13.0%) | 8 (9.5%) | ||
| Child-Pugh score, n (%) | 0.47 | 0.128 | |||
| A | 119 (86.2%) | 48 (88.9%) | 71 (84.5%) | ||
| B | 19 (13.8%) | 6 (11.1%) | 13 (15.5%) | ||
| Size ≥ 5cm*, n (%) | 110 (79.7%) | 45 (83.3%) | 65 (77.4%) | 0.40 | −0.149 |
| Tumor extent, n (%) | 0.53 | 0.108 | |||
| Unilobar | 85 (61.6%) | 35 (64.8%) | 50 (59.5%) | ||
| Bilobar | 53 (38.4%) | 19 (35.2%) | 34 (40.5%) | ||
| PVTT, n (%) | 48 (34.8%) | 15 (27.8%) | 33 (39.3%) | 0.13 | 0.270 |
| Vp1 | 1 (0.7%) | 0 (0%) | 1 (1.2%) | ||
| Vp2 | 11 (8.0%) | 5 (9.3%) | 6 (7.1%) | ||
| Vp3 | 24 (17.4%) | 7 (13.0%) | 17 (20.2%) | ||
| Vp4 | 12 (8.7%) | 3 (5.6%) | 9 (10.7%) | ||
| BCLC stage, n (%) | 0.64 | 0.070 | |||
| A | 35 (25.4%) | 13 (24.1%) | 22 (26.2%) | ||
| B | 48 (34.8%) | 22 (40.7%) | 26 (31.0%) | ||
| C | 55 (39.9%) | 19 (35.2%) | 36 (42.9%) | ||
| TNM stage, n (%) | 0.22 | 0.233 | |||
| IA | 2 (1.4%) | 1 (1.8%) | 1 (1.2%) | ||
| IB | 36 (26.1%) | 19 (35.2%) | 17 (20.2%) | ||
| II | 19 (13.8%) | 3 (5.6%) | 16 (19.0%) | ||
| IIIA | 39 (28.3%) | 16 (29.6%) | 23 (27.4%) | ||
| IIIB | 24 (17.4%) | 11 (20.4%) | 13 (15.5%) | ||
| IVA | 15 (10.9%) | 3 (5.6%) | 12 (14.3%) | ||
| IVB | 3 (2.2%) | 1 (1.8%) | 2 (2.4%) | ||
| HKLC stage, n (%) | 0.90 | −0.037 | |||
| I | 22 (15.9%) | 8 (14.8%) | 14 (16.7%) | ||
| IIa | 1 (0.7%) | 0 (0.0%) | 1 (1.2%) | ||
| IIb | 49 (35.5%) | 21 (38.9%) | 28 (33.3%) | ||
| IIIa | 5 (3.6%) | 3 (5.6%) | 2 (2.4%) | ||
| IIIb | 55 (39.9%) | 19 (35.2%) | 36 (42.9%) | ||
| IVa | 1 (0.7%) | 2 (3.7%) | 2 (2.4%) | ||
| Vb | 1 (0.7%) | 1 (1.8%) | 1 (1.2%) | ||
| Okuda stage, n (%) | 0.90 | 0.097 | |||
| I | 110 (79.7%) | 43 (79.6%) | 67 (79.8%) | ||
| II | 24 (17.4%) | 11 (20.4%) | 13 (15.5%) | ||
| III | 4 (2.9%) | 0 (0.0%) | 4 (4.8%) | ||
| AFP ≥ 200 ng/mL, n (%) | 46 (33.3%) | 17 (31.5%) | 29 (34.5%) | 0.71 | 0.065 |
| Beyond the Milan criteria, n (%) | 120 (87.0%) | 46 (85.2%) | 74 (88.1%) | 0.62 | 0.085 |
Note: *Size of primary index tumor.
Abbreviations: AFP, serum alpha-fetoprotein; ECOG, Eastern Cooperative Oncology Group; HKLC, Hong Kong Liver Cancer; PVTT, portal vein tumor thrombosis; TACE, trans-arterial chemoembolization; TARE, trans-arterial radioembolization; SMD, standardized mean difference; TNM, Tumor, nodes, metastasis.